HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Settlements Without Penalties Spur Compliance More Than Litigation – FTC Commissioner

Executive Summary

Non-monetary settlements are more effective than litigation at changing consumer product companies’ advertising practices, says FTC Commissioner Christine Wilson. “We see non-monetary settlements curtail behavior and require sometimes fundamental changes in the way companies do business.”

You may also be interested in...



US Business Lobby Opposes Retroactivity If Congress Restores FTC Monetary Relief Authority

US Chamber of Commerce’s position to deny retroactive applicability in collecting monetary relief under the FTC Act against advertising violators would provide a “gaping loophole” for violators to escape consequences and encourage future misdeeds, says FTC acting chairwoman Rebecca Kelly Slaughter.

FTC Will Ask Congress To Sharpen Monetary Relief Authority Dulled By Supreme Court Ruling

Justice Breyer suggests FTC ask Congress to strengthen its enforcement rules. It is “free to ask Congress to grant it further remedial authority,” according to court opinion stating a rule the FTC has wielded for forty years to impose financial penalties doesn’t grant it authority to obtain equitable monetary relief.

Same Old Supplement Claim Violations Prompt US Regulators’ Action Under New COVID-19 Authority

FTC files complaint against Quickwork as first action under authority granted in the COVID-19 Consumer Protection Act. The enforcement came after the firm twice ingored warnings to discontinue claims its vitamin D and zinc supplements were equal to or more effective than current vaccines.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS150541

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel